Published

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of palliative medicine
Date: 2022-08-01
Source: PubMed
DOI: 10.1089/jpm.2022.0036
PubMed: 35285721

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction End-of-Life Distress Treatment-Resistant Depression Healthcare Workers Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).ClinicalTrials.gov · 2023-11-29 A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-13 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14